This company has been acquired
Cardiovascular Systems Future Growth
Future criteria checks 1/6
Key information
35.4%
Earnings growth rate
34.2%
EPS growth rate
| Medical Equipment earnings growth | 12.7% |
| Revenue growth rate | 11.1% |
| Future return on equity | n/a |
| Analyst coverage | Good |
| Last updated | 09 Feb 2023 |
Recent future growth updates
Recent updates
We're Not Very Worried About Cardiovascular Systems' (NASDAQ:CSII) Cash Burn Rate
Feb 03
We're Hopeful That Cardiovascular Systems (NASDAQ:CSII) Will Use Its Cash Wisely
Oct 12Cardiovascular Systems reports Q4 earnings miss; provides FY23 revenue guidance in-line with estimates
Aug 03Here's Why Cardiovascular Systems, Inc.'s (NASDAQ:CSII) CEO Compensation Is The Least Of Shareholders' Concerns
Nov 05Are Investors Undervaluing Cardiovascular Systems, Inc. (NASDAQ:CSII) By 36%?
Oct 09At US$36.59, Is It Time To Put Cardiovascular Systems, Inc. (NASDAQ:CSII) On Your Watch List?
Sep 18Are Investors Undervaluing Cardiovascular Systems, Inc. (NASDAQ:CSII) By 28%?
Jun 24Is Now The Time To Look At Buying Cardiovascular Systems, Inc. (NASDAQ:CSII)?
Jun 03We're Interested To See How Cardiovascular Systems (NASDAQ:CSII) Uses Its Cash Hoard To Grow
Apr 29Should You Take Comfort From Insider Transactions At Cardiovascular Systems, Inc. (NASDAQ:CSII)?
Mar 17Cardiovascular Systems (NASDAQ:CSII) Shareholders Have Enjoyed A Whopping 399% Share Price Gain
Feb 10Cardiovascular Systems misses on revenue
Feb 03Need To Know: Cardiovascular Systems, Inc. (NASDAQ:CSII) Insiders Have Been Selling Shares
Dec 11
Cardiovascular Systems, Inc. 2021 Q1 - Results - Earnings Call Presentation
Nov 06Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 6/30/2025 | 321 | -12 | N/A | N/A | 2 |
| 6/30/2024 | 283 | -19 | N/A | N/A | 6 |
| 6/30/2023 | 257 | -27 | N/A | N/A | 6 |
| 12/31/2022 | 240 | -38 | -34 | -29 | N/A |
| 9/30/2022 | 238 | -39 | -31 | -27 | N/A |
| 6/30/2022 | 236 | -37 | -28 | -24 | N/A |
| 3/31/2022 | 245 | -33 | -17 | -13 | N/A |
| 12/31/2021 | 252 | -29 | -17 | -13 | N/A |
| 9/30/2021 | 257 | -20 | -13 | -10 | N/A |
| 6/30/2021 | 259 | -13 | -5 | -1 | N/A |
| 3/31/2021 | 231 | -23 | -18 | -14 | N/A |
| 12/31/2020 | 228 | -20 | -16 | -11 | N/A |
| 9/30/2020 | 233 | -24 | -14 | -9 | N/A |
| 6/30/2020 | 237 | -27 | -17 | -13 | N/A |
| 3/31/2020 | 262 | -11 | 0 | 4 | N/A |
| 12/31/2019 | 264 | -7 | 1 | 5 | N/A |
| 9/30/2019 | 256 | -3 | 2 | 6 | N/A |
| 6/30/2019 | 248 | 0 | 7 | 10 | N/A |
| 3/31/2019 | 239 | 2 | 9 | 13 | N/A |
| 12/31/2018 | 231 | 2 | 11 | 14 | N/A |
| 9/30/2018 | 224 | 1 | 8 | 11 | N/A |
| 6/30/2018 | 217 | 2 | 7 | 10 | N/A |
| 3/31/2018 | 211 | -1 | 2 | 5 | N/A |
| 12/31/2017 | 207 | -3 | 2 | 5 | N/A |
| 9/30/2017 | 205 | -2 | 17 | 19 | N/A |
| 6/30/2017 | 205 | -2 | 18 | 20 | N/A |
| 3/31/2017 | 199 | -7 | 11 | 13 | N/A |
| 12/31/2016 | 191 | -28 | 6 | 8 | N/A |
| 9/30/2016 | 183 | -45 | N/A | -21 | N/A |
| 6/30/2016 | 177 | -56 | N/A | -24 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CSII is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CSII is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CSII is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CSII's revenue (11.1% per year) is forecast to grow faster than the US market (7% per year).
High Growth Revenue: CSII's revenue (11.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CSII's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/04/27 02:34 |
| End of Day Share Price | 2023/04/27 00:00 |
| Earnings | 2022/12/31 |
| Annual Earnings | 2022/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cardiovascular Systems, Inc. is covered by 20 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Nathan Weinstein | Aegis Capital Corporation |
| Lawrence Neibor | Baird |
| Matt Miksic | Barclays |